Vivos Therapeutics
VVOS
27 hedge funds and large institutions have $6.66M invested in Vivos Therapeutics in 2022 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 11 increasing their positions, 6 reducing their positions, and 7 closing their positions.
83% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 6
33% more capital invested
Capital invested by funds: $5.02M → $6.66M (+$1.63M)
0.04% more ownership
Funds ownership: 0.39% → 0.43% (+0.04%)
7% less funds holding
Funds holding: 29 → 27 (-2)
28% less call options, than puts
Call options by funds: $91K | Put options by funds: $126K
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$445K |
| 2 |
Russell Investments Group
London,
United Kingdom
|
+$313K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$236K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$164K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$83.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$275K |
| 2 |
Two Sigma Investments
New York
|
-$264K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$111K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$68.2K |
| 5 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$43K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AFM
26
Anson Funds Management
Dallas,
Texas
| – | -$275K | -4,892 | Closed |
|
|
27
Two Sigma Investments
New York
| – | -$264K | -4,689 | Closed |
|
|
28
Citadel Advisors
Miami,
Florida
| – | -$68.2K | -1,043 | Closed |
|
|
29
Cambridge Investment Research Advisors
Fairfield,
Iowa
| – | -$43K | -768 | Closed |
|
30
UBS Group
Zurich,
Switzerland
| – | -$38K | -683 | Closed |
|
|
AIA
31
Avalon Investment & Advisory
Houston,
Texas
| – | -$34K | -611 | Closed |
|
32
Wells Fargo
San Francisco,
California
| – | -$5.23K | -80 | -95% |
|
VVOS Hedge Fund Activity: Q1 2022 in Review
27 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Vivos Therapeutics (VVOS) for Q1 2022, worth a combined $6.66M — up 33% from $5.02M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of VVOS and 5 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 11 added.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $445K. The largest seller was Anson Funds Management, exiting entirely with an estimated $275K sold.
- 27 institutional investors held Vivos Therapeutics (VVOS) as of Q1 2022, down from 29 in Q4 2021.
- Funds reported $6.66M of Vivos Therapeutics stock for Q1 2022, up 33% quarter-over-quarter.
- 5 funds opened new Vivos Therapeutics positions in Q1 2022 and 7 closed out, a net change of -2 holders.
- The largest Vivos Therapeutics buyer in Q1 2022 was Point72 Asset Management, an estimated $445K added.
- The largest Vivos Therapeutics seller in Q1 2022 was Anson Funds Management, an estimated $275K sold.
Based on aggregated 13F filings for Q1 2022.